The $70M Recall Changing Breast Biopsies and Private Equity Payouts

How a single recalled biopsy needle wiped out Hologic’s CVR growth target and triggered nationwide patient delays.

In corporate finance, precision is measured to four decimal places. In breast imaging, it is measured in weeks of waiting.

When Hologic pulled a single biopsy needle off the market, it set off two countdowns: one deciding a nine-figure payout for former shareholders, and another dictating how long a woman waits between an abnormal mammogram and a diagnosis.

When private equity firms Blackstone and TPG acquired Hologic for $18.3 billion on April 7, 2026, stockholders received $76 per share in cash alongside a Contingent Value Right (CVR)—a specialized financial instrument designed to reward former investors if Hologic’s core Breast Health division hits strict revenue targets.

To trigger the first payout in fiscal 2026, segment revenue must clear a baseline floor of $1,556,844,377, which unlocks a $0.50 per CVR distribution. Revenue reaching or exceeding $1,571,844,377 yields the maximum $1.50 payout, with any figure falling within that band determined via linear interpolation. A second tranche of up to $1.50 hinges on fiscal 2027 performance, backed by a catch-up milestone set at $1,666,256,283.

These payout thresholds sit against a known operational baseline. Hologic reported Breast Health revenue of $369.1 million, $356.2 million, $365.2 million, and $393.7 million across the four quarters of fiscal 2025, bringing the full-year segment total to $1,484.2 million. Clearing the minimum CVR threshold requires roughly 4.9% annual growth—an additional $72.6 million in top-line revenue—while securing the full $1.50 requires approximately 5.9% growth.

Six weeks after signing the merger agreement, Hologic halted shipments of a core biopsy needle.

In November 2025, the company suspended distribution of the Brevera Breast Biopsy System Disposable 9 Gauge Needle following an internal review of post-market safety data. The review identified 108 complaints against 677,307 shipped units, confirming 16 instances where stainless steel or polyethylene fragments remained in patient tissue or biopsy specimens. On January 2, 2026, Hologic issued a customer letter removing all inventory from the market due to risks of foreign body reaction, hematoma, hemorrhage, and infection. The FDA formally posted a Class 2 recall on February 6, 2026.

The direct financial weight of the recall surfaced in Hologic’s regulatory filings in January. Revenue from Brevera 9 Gauge Needles and related products accounted for approximately 4.7% of Breast Health revenue in fiscal 2025—representing roughly $69.8 million in historical sales.

Setting the financial parameters side by side reveals a striking symmetry: clearing the initial CVR threshold required $72.6 million in new revenue growth, while the product line withdrawn from the market accounted for $69.8 million.

Hologic informed shareholders in January that achieving the 2026 milestone would be "more challenging" and noted that the risk-adjusted net present value of each CVR had fallen below the $2.54 estimate published in the proxy statement. For the first quarter of fiscal 2026, Hologic reported Breast Health revenue of $375.9 million, up 1.8% year over year. Maintaining the minimum CVR pace requires averaging $389.2 million per quarter, leaving Q1 approximately $13.3 million behind the required trajectory during a period when the shipment pause took effect mid-quarter.

The operational consequences quickly expanded from deal documentation into clinical practice.

On March 13, 2026, the FDA placed stereotactic breast biopsy needles on its Medical Device Shortages List. The American College of Radiology formally notified the FDA in May regarding widespread care disruptions. On June 16, the FDA issued a Letter to Health Care Providers confirming that manufacturing disruptions are expected to affect patient management through the first quarter of 2027, advising facilities to implement supply conservation strategies.

In clinical settings, conservation guidelines translate into rationing protocols, prioritizing urgent cases and delaying procedures for patients with lower-risk diagnostic findings. Hologic has responded by expanding manufacturing for its alternative Eviva needle line, enabling Brevera consoles to operate as standalone specimen radiography systems, and securing FDA 510(k) clearance for a modified Brevera needle, targeting a full return to market by late calendar 2026. However, because Eviva systems rely on different procedural protocols, device substitution requires operational adjustments for working radiology departments.

A significant information gap now emerges as fiscal 2026 closes in late September.

Following its private equity buyout and Nasdaq delisting, Hologic is no longer required to publish quarterly earnings releases or segment breakdowns. CVR holders will receive payout determinations privately through Equiniti Trust Company as rights agent, leaving former shareholders without secondary market pricing or public financial disclosures.

Consequently, two distinct countdowns reach critical junctures on separate schedules.

The private financial measurement window that governs a nine-figure transfer to former shareholders closes at the end of September 2026.

Meanwhile, the public health supply disruption that governs how long patients wait for stereotactic biopsies extends into early 2027.

The Luteal reports on the business, science, and policy of women's health. This content is for informational purposes and does not constitute medical advice. Patients with questions regarding breast imaging or scheduled procedures should consult their healthcare provider.

--- Sources

Primary

Hologic, Inc. Form 8-K, October 21, 2025. CVR structure, interpolation mechanics and the $1,556,844,377 and $1,571,844,377 thresholds. Hologic, Inc. Form 8-K, January 2026 (SEC accession 000119312526022672). Brevera stop ship and recall, the 4.7% of fiscal 2025 Breast Health revenue figure, the "more challenging" language, the $1,666,256,283 catch-up milestone and the $2.54 per CVR proxy estimate. Hologic, Inc. Form 8-K, April 7, 2026 (SEC accession 000119312526144632), including the CVR Agreement filed as Exhibit 10.1. Closing terms, Equiniti Trust Company as rights agent. Hologic, Inc. Form 10-Q for the quarter ended December 27, 2025. Breast Health revenue of $375.9 million, up 1.8%. Hologic fiscal 2025 quarterly earnings releases (Q1 through Q4). Segment revenue of $369.1M, $356.2M, $365.2M and $393.7M. FDA, "Disruptions in Availability of Breast Biopsy Needles," Letter to Health Care Providers, June 16, 2026. Shortage duration through end of Q1 2027, conservation recommendation, March 13 addition of product code KNW to the Medical Device Shortages List. Hologic customer letter, January 2, 2026, and Hologic Brevera product page. Removal of all lots, Eviva expansion, standalone specimen radiography, 510(k) clearance and end-of-2026 return-to-market target.

Company-stated

The 4.7% share of fiscal 2025 Breast Health revenue attributable to Brevera 9 Gauge Needles and related products. Hologic's assessment that the risk-adjusted net present value of one CVR is likely below $2.54. Hologic's return-to-market timing and mitigation measures.

Luteal-computed

Fiscal 2025 Breast Health segment total of $1,484.2 million, summed from four reported quarters. Growth of 4.9% and 5.9% required to reach the two fiscal 2026 CVR thresholds. The $72.6 million gap between fiscal 2025 actual and the first threshold. The roughly $69.8 million implied value of Brevera 9 Gauge Needles and related products. The $389.2 million per-quarter pace implied by the first threshold and the $13.3 million Q1 shortfall against it.

Secondary, labeled in text

Ryan Zimmerman, BTIG, on the likelihood of the FY2027 payment, reported March 2026. American College of Radiology update of May 14, 2026 and letter to FDA of May 11, 2026.